The Evidence Layer
for Consumer Health

Rationale

"Evidence Layer" is clearer than "Operating System" for food-industry investors. Glico understands evidence — their GABA chocolate line is built on functional claims. This positions Syntropy as infrastructure that proves products work, not just another consumer app.

Talking Points

• "The supplement market is $280 billion globally — larger than the music, gaming, and streaming industries combined."
• "Yet there is no evidence infrastructure. When a consumer buys a supplement, no one tracks whether it works. Not the brand, not their doctor, not them."
• "We are building that missing layer — the evidence infrastructure that connects consumers, brands, and outcomes for the first time."
• "Our endgame isn't analytics — it's precision dietary science. Today's supplement industry operates on marketing budgets, not evidence. We're building the infrastructure that makes health outcomes observable and measurable, creating a world where products compete on results, not ad spend."
• Transition: "Let me show you what this gap looks like for brands."

Anticipated QA

• Q: What do you mean by "evidence layer"?
  A: We provide the protocol layer, adherence tracking, and AI that sits between brands and consumers — generating the first longitudinal dataset of supplement usage and outcomes. Think of it as clinical-grade tracking applied to consumer wellness.
• Q: Why "evidence" and not "data"?
  A: Data is raw. Evidence is structured, contextual, and actionable. We don't just collect data points — we generate evidence that a product works, that a consumer is adherent, that a protocol drives outcomes. Evidence is what brands need for claims substantiation and what consumers need to trust their purchase.
• Q: What do you mean by 'precision dietary science'?
  A: The same way precision medicine uses genomics to personalize treatment, precision dietary science uses longitudinal adherence data — what people actually take, how consistently, and what outcomes they report — to understand which protocols work for which populations. Nobody has this data today. We're building the collection infrastructure.

Sources

• Global supplement market: Grand View Research, 2024 ($280.1B)
• "Zero evidence infrastructure" validated by interviews with 12 DTC supplement founders — none track post-purchase adherence